**Original Article**

**Dysbalanced sex hormone status is an independent predictor of decompensation and mortality in patients with liver cirrhosis**

Rafael Paternostro,¹,² Birgit B. Heinisch,¹,² Thomas Reiberger,¹,² Mattias Mandorfer,¹,² Constanze Bardach,⁴ Katharina Lampichler,⁴ Berit Seeland,¹,² Remy Schwarzer,¹,² Michael Trauner,² Markus Peck-Radosavljevic³ and Arnulf Ferlitsch¹,²

¹Vienna Hepatic Hemodynamic Laboratory, Division of Gastroenterology and Hepatology, Department of Internal Medicine III, ²Division of Gastroenterology and Hepatology, Department of Internal Medicine III, and ³Department of Biomedical Imaging and Image-guided Therapy, Medical University of Vienna, Vienna, Hephatology, Endocrinology and Nephrology, Klinikum Klagenfurt am Wörthersee, Klagenfurt, Austria

**Aims:** Endocrinological abnormalities, including low testosterone levels, are prevalent in cirrhosis. We assessed sexual hormone status in regard to hemodynamic abnormalities and its impact on hepatic decompensation and survival.

**Methods:** Males with cirrhosis were prospectively included in this study since 2010. Sexual hormones including bioavailable testosterone, total testosterone, luteinizing hormone, follicle-stimulating hormone, prolactin, and sex hormone-binding globulin as well as Child–Pugh score, Model for End-stage Liver Disease (MELD) score, and hepatic venous pressure gradient were recorded. Sarcopenia was also assessed in patients with available computed tomography scans. Clinical follow-up for hepatic decompensation, liver transplantation, and death was recorded until May 2017.

**Results:** One hundred fourteen male cirrhotic patients were included: age 55 ± 9.4 years, MELD 13.5 (range, 7–20.7). Etiologies were alcoholic liver disease in 61 (53.5%) patients, viral in 30 (26.3%) patients, and other in 23 (20.2%). Child–Pugh scores were A in 32 (28.1%) patients, B in 48 (42.1%), and C in 34 (29.8%). Levels of bioavailable testosterone and total testosterone decreased with advanced Child–Pugh score ($P < 0.001$ and $P < 0.001$) whereas prolactin increased ($P = 0.002$). Median bioavailable testosterone (0.8 ng/mL [0.1–2] vs. 1.68 ng/mL [0.07–2.65]; $P = 0.004$) and total testosterone (2.7 ng/mL [0.23–12.34] vs. 7 ng/mL [0.25–10]; $P = 0.041$) levels were lower in patients with severe portal hypertension (hepatic venous pressure gradient $> 12$ mmHg). Median bioavailable testosterone (0.25 ng/mL [0.07–1.7] vs. 0.97 ng/mL [0.15–2.74]); $P = 0.017$) and total testosterone levels (1.28 ng/mL [0.25–7.32] vs. 4.32 ng/mL [0.43–13.47]; $P = 0.031$) were significantly lower in sarcopenic patients. Median follow-up was 13 months (0.2–75 months) and liver-related events were recorded in 46 patients (40.4%; death, 31 [27.2%]). Low total testosterone was associated with an increased risk for hepatic decompensation and/or death, even after adjusting for Child–Pugh score, MELD, and other relevant factors (Child–Pugh score model: hazard ratio 2.503, 95% confidence interval, 1.214–5.157, $P = 0.013$; MELD model: hazard ratio 3.065, 95% confidence interval, 1.523–6.169, $P = 0.002$).

**Conclusion:** In parallel to increasing severity of cirrhosis, levels of testosterone decline whereas prolactin levels increase. However, low testosterone levels are independently associated with a higher risk for hepatic decompensation and mortality.

**Key words:** cirrhosis, mortality, sexual hormone, testosterone

---

**INTRODUCTION**

THE HYPOTHALAMIC–PITUITARY–GONADAL (HPG) axis is pathologically profoundly altered in cirrhotic patients. This is attributed to both a gonadal and hypothalamus–pituitary dysfunction, although the process itself is not yet fully understood.1–5 Low serum testosterone (T) levels are frequently found in cirrhotic men and correlate...
well with severity of liver disease.1,6,7 Primary hypogonadism due to direct suppression of the testis, for example, through ethanol, as well as secondary/central hypogonadism due to inadequately normal luteinizing hormone (LH)/downregulated gonadotropin-releasing hormone (GnRH) release have been described.1–4,8 Conflicting results have been published regarding LH levels in cirrhosis. Physiologically LH levels should be increased in the state of low T; however, in cirrhosis, reports vary between normal, increased, or even decreased LH.1,2,8–10 Along with Leydig cell dysfunction, hypothalamic dysfunction and direct inhibition of LH secretion through hyperestrogenism, which is known to occur due to a combination of increased peripheral aromatization of androgens and portosystemic shunting11,12 are thought to contribute towards this abnormality.5

More recent studies have focused on the prognostic impact of T in the course of advanced liver disease. Low androgens and elevated serum estrone were associated with higher Model for End-stage Liver Disease (MELD) score and individual adverse health outcomes.6 Association of low T with mortality13 within 12 months of follow-up was also described, but no impact on hepatic decompensation.14 Furthermore, hepatic steatosis and presence of non-alcoholic fatty liver disease is significantly associated with low serum T levels.15 However, data on the predictive value of sex hormones, and especially T, for liver-related clinical events were recorded. Decompensation was defined as hospitalization for acute decompensation of cirrhosis such as: variceal bleeding, jaundice, occurrence or worsening of ascites, HE, spontaneous bacterial peritonitis, and hepatorenal syndrome. In those who were already diagnosed with ascites at baseline, significant worsening of ascites was also considered to denote acute decompensation of cirrhosis. Follow-up was obtained until May 2017.

Treatment strategies
The treatment strategy of our outpatient clinic was based on the national consensus statements that were available during the study period.16,17 The Billroth I and II consensuses were based on the international clinical practice recommendations at the time of publication. In brief, non-selective β-blockers (NSBB) were preferred over endoscopic variceal ligation (EVl) for primary prophylaxis of variceal bleeding. In case of contraindications for NSBB therapy, EVL was carried out. For secondary prophylaxis, NSBB in combination with EVL was the therapy of choice; treatment failures were evaluated for transjugular intrahepatic portosystemic shunt (TIPS). Patients with ascites were treated with paracentesis plus albumin and diuretics, as well as TIPS, if indicated.18 Patients with HE were treated with lactulose and/or rifaximin.17

Nutritional status, as part of diagnostic work-up, was routinely assessed in inpatients and outpatients with cirrhosis. Patients were counseled to meet their daily energy intake of 35–40 kcal/kg and a protein intake of 1.2–1.5 g/kg body weight, according to the recommendations available during the study period.19,20 High-energy protein drinks were recommended to patients at risk of malnutrition.19 Furthermore, dietary counselling was available for all patients at their own request.

© 2018 The Authors.
Hepatology Research published by John Wiley & Sons Australia, Ltd on behalf of Japan Society of Hepatology
Measurement of sex hormones

Total testosterone, SHBG, LH, FSH, and PRL were analyzed using electrochemiluminescence immunoassay (ECLI A; Roche Diagnostics, Vienna, Austria). Bioavailable T (= free T plus albumin-bound T) was then calculated automatically through the Department of Laboratory Medicine using the Vermeulen formula. To avoid laboratory deviation due to the circadian rhythm of sexual hormones and especially T, blood used for analyzing sex hormones was assessed during routine laboratory analysis in fasting conditions in the morning.

Hepatic venous pressure gradient measurement

The right internal jugular vein was accessed under ultrasound guidance and local anesthesia with the Seldinger technique using a catheter introducer set (8.5 Fr; Arrow International, Reading, PA, USA). Then a balloon catheter (7 Fr Ferlitsch HVPG catheter; Pejcl Medizintechnik, Vienna, Austria) was chosen to cannulate the liver vein through the transjugular access as described previously. Clinically significant portal hypertension (CSPH) was defined as an HVPG ≥10 mmHg.

Assessment of sarcopenia

Computed tomography scans within 1 year of study inclusion were taken into account. All measurements were obtained on axial contrast-enhanced CT scans of the abdomen. The cross-sectional muscle area was calculated in all patients at the level of the third lumbar vertebrae (L3) using OsiriX medical imaging software for iOS (version 7.5; Pixmeo, Bernex, Switzerland) and syngo.via software (version VB30; Siemens Healthcare, Erlangen, Germany). The skeletal muscle index was defined as the total cross-sectional area of all abdominal muscles (rectus abdominis, oblique and transverse abdominal muscles, paraspinal muscles, and the psoas muscles) at the level of L3 on a single scan image normalized by height. Results are shown in cm²/m². A senior radiology resident and an attending specialized in abdominal radiology analyzed all variables independently and the mean value of both measurements was taken into account for statistical analysis. Sarcopenia was defined according to a previously proposed cut-off: <42 cm²/m².

Statistical analysis

Continuous variables were reported as mean ± standard deviation or median (95% confidence interval [CI]), and categorical variables were reported as number (n) of patients with the certain characteristic (proportion of patients with the certain characteristic [%]). Spearman rho-coefficient was used to detect correlations between two variables where at least one was distributed nonparametric, and/or categorized as an ordinal variable. Student’s t-test was used for group comparisons of normally distributed data, and the Mann–Whitney U-test where data were not normally distributed. Kruskal–Wallis H-test and post-hoc comparisons were used to compare medians in groups of three or more. The significance level was adjusted using the Bonferroni method. Pearson’s χ²-test or Fisher’s exact test were used for group comparisons. The Youden index was used to determine optimal cut-offs regarding death and decompensation for BT, TT, and PRL. The impact of T on mortality, decompensation, and transplant-free survival was analyzed using semiparametric proportional hazard Cox models. Univariate Cox regression was carried out to determine factors significantly associated with the composite end-point (hepatic decompensation and/or death). Then all univariate significant factors were included in four separate multivariate models to avoid multicollinearity between CPS/MELD and BT/TT. Patients entered the model on the day that blood was drawn for analyzing sexual hormone levels and were followed until either death or liver transplantation. Hepatic decompensation during follow-up was recorded as defined above. Patients who received liver transplantation were censored at the day of surgery. The log–rank test was used to find differences in survival times between the groups that were stratified according to the previously determined cut-offs (Youden index). Two-sided P-values <0.05 were considered statistically significant. The IBM SPSS 24.0 statistics software (SPSS, Armonk, NY, USA) was used for all statistical analyses and Kaplan–Meier curves.

Ethics

This study was approved by the ethics committee of the Medical University of Vienna (study no. 450/2010) and undertaken in accordance to the current version of the Helsinki Declaration. All patients signed an informed consent form prior to study inclusion.

RESULTS

A total of 114 patients were included. Main patient characteristics are listed in Table 1 and univariate correlation of sex hormones and parameters of liver function in Table 2. We determined optimal cut-offs regarding hepatic decompensation and mortality using the Youden index: BT <1.59 ng/mL, TT <6.25 ng/mL, and PRL >13.8 ng/mL.
Table 1 Main patient characteristics

|                      | All  | CPS A | CPS B | CPS C | P-value overall |
|----------------------|------|-------|-------|-------|-----------------|
|                      | n = 114 | n = 32 | n = 48 | n = 34 |                 |
| Age, mean ± SD       | 55 ± 9.2 | 51.7 ± 9.4 | 57.4 ± 9.1 | 56.2 ± 8.5 | A vs. B, 0.018 |
|                      |        | A vs. C, 0.113 | B vs. C, 0.816 |      |                 |
| Etiology, n (%)      |       |       |       |       |                 |
| ALD                  | 61 (53.5) | 16 (26.2) | 25 (41.0) | 20 (32.8) | 0.634           |
| Viral                | 30 (26.3) | 10 (33.3) | 15 (50.0) | 5 (16.7)  |                 |
| COMB                 | 9 (7.9)  | 2 (22.2)  | 4 (44.4)  | 3 (33.3)  |                 |
| Other                | 14 (12.3) | 4 (28.6)  | 4 (28.6)  | 6 (42.9)  |                 |
| HCC                  | 62 (54.0) | 2 (6.3)   | 28 (58.0) | 32 (94.0) | <0.001          |
|                      |       |         |       |       |                 |
| Ascites, n (%)       | 62 (54.0) | 2 (6.3)   | 28 (58.0) | 32 (94.0) | <0.001          |
|                      |       |         |       |       |                 |
| Grade 0–1            | 52 (45.6) | 30 (57.7) | 20 (38.5) | 2 (3.8)   |                 |
| Grade 2              | 35 (30.7) | 2 (5.7)   | 19 (54.3) | 14 (40.0) |                 |
| Grade 3              | 27 (23.7) | 0 (0.0)   | 9 (33.3)  | 18 (66.7) |                 |
| Death, n (%)         | 31 (27.0) | 7 (21.9)  | 16 (51.6) | 10 (32.3) | 0.206           |
| Decompenation during follow-up, n (%) | 35 (30.7) | 7 (21.9)  | 16 (51.6) | 10 (32.3) | 0.206           |
|                      |       |         |       |       |                 |
| Days of follow-up, n (%) | 397   | 1421.5 | 449.5 | 192.5 | A vs. B, 0.019 |
|                      |       |         |       |       | A vs. C, <0.001 |
|                      |       |         |       |       | B vs. C, 0.004 |
| MELD, median (95% CI) | 13.56 (7.0–20.7) | 8.4 (6.43–15.3) | 13.1 (9.7–18.86) | 17.1 (13.5–23) | <0.001 |
| HVPG, mmHg, mean ± SD† | 16.8 ± 6 | 13 ± 5.5 | 19.3 ± 4.8 | 19.8 ± 5.4 | A vs. B, 0.001 |
|                      |       |         |       |       | A vs. C, 0.004 |
|                      |       |         |       |       | B vs. C, 0.963 |
| CSPH, n (%)          | 45 (91.8) | 16 (35.6) | 19 (42.2) | 10 (22.2) | 0.043           |
| No CSPH, n (%)       | 4 (8.2)  | 4 (100.0) | 0 (0.0)  | 0 (0.0)  |                 |
| Bioavailable T, median (95% CI) | 1.12 (0.12–2.58) | 1.66 (0.68–3.41) | 1.07 (0.14–1.95) | 0.39 (0.1–1.5) | <0.001 |
| Total T, median (95% CI) | 4.38 (0.32–11.62) | 7.18 (2.97–16.33) | 4.39 (0.37–9.6) | 1.49 (0.25–8) | <0.001 |
| LH, median (95% CI)  | 6.2 (1.72–15.18) | 6.9 (2.56–39.56) | 6.45 (1.57–15.26) | 5.1 (0.1–15.55) | A vs. B, 0.861 |
|                      |       |         |       |       | A vs. C, 0.068 |
|                      |       |         |       |       | B vs. C, 0.072 |
| SHBG, mean ± SD      | 93.65 ± 43.5 | 109.1 ± 49.86 | 94.29 ± 38.9 | 78.2 ± 38.5 | A vs. C, 0.011 |
|                      |       |         |       |       | A vs. B, 0.384 |
|                      |       |         |       |       | B vs. C, 0.279 |
| FSH, median (95% CI) | 6.9 (1.63–23.62) | 7.5 (2.44–30) | 6.55 (2–30.86) | 5.6 (0.6–23) | A vs. B, 0.272 |
|                      |       |         |       |       | A vs. C, 0.115 |
|                      |       |         |       |       | B vs. C, 0.351 |
| PRL, median (95% CI) | 13.45 (5.24–42.23) | 8.4 (3.4–38, n = 24) | 13.45 (5.85–34, n = 34) | 16 (7.65–73.61, n = 30) | A vs. B, 0.039 |
|                      |       |         |       |       | A vs. C, 0.001 |
|                      |       |         |       |       | B vs. C, 0.040 |

†Available in 49 patients.
‡Available in 88 patients.
ALD, alcoholic liver disease; COMB, Viral + ALD; CI, confidence interval; CPS, Child–Pugh score; CSPH, clinically significant portal hypertension; FSH, follicle-stimulating hormone; HCC, hepatocellular carcinoma; HVPG, hepatic venous pressure gradient; LH, luteinizing hormone; LTX, liver transplantation; MELD, Model for End-stage Liver Disease; PRL, prolactin; SHBG, sex hormone-binding globulin; T, testosterone.

© 2018 The Authors.
Hepatology Research published by John Wiley & Sons Australia, Ltd on behalf of Japan Society of Hepatology
Sex hormones and parameters of liver function

As shown in Table 1, BT and TT significantly decreased over CPS stages \((P < 0.001)\). Prolactin significantly increased over CPS stages \((P = 0.002)\). Sex hormone-binding globulin was significantly lower between CPS A vs. C \((P = 0.014)\), but no difference between A vs. B or B vs. C was found. For correlations of sex hormones with markers of liver disease see Table 2. Figure 1 shows median levels of sexual hormones over CPS. Furthermore, the distribution of patients found with BT, TT, and PRL levels below respectively above the threshold (determined via Youden index) showed significantly more patients with low BT \((P < 0.001)\) and low TT \((P < 0.001)\) and elevated PRL levels \((P < 0.001 \text{ and } P = 0.025)\) with increasing CPS and ascites stages (Fig. 2).

Sex hormones and ascites

Median levels of BT (ascites grade 0–1 vs. \(2 P = 0.001\); 0–1 vs. 3 \(P \leq 0.001\); 2 vs. 3 \(P = 0.001\)) and TT (ascites grade 0–1 vs. 2 \(P = 0.009\); 0–1 vs. 3 \(P \leq 0.001\); 2 vs. 3 \(P \leq 0.001\)) significantly decreased with increasing severity of ascites. Prolactin levels increased (ascites grade 0–1 vs. 2 \(P = 0.113\); 0–1 vs. 3 \(P = 0.005\); 2 vs. 3 \(P = 0.052\)). In addition, distribution of patients found with BT, TT, and PRL levels below respectively above the threshold (determined by the Youden index) showed significantly more patients with low BT \((P < 0.001)\), low TT \((P < 0.001)\), and elevated PRL \((P = 0.025)\) with increasing ascites grades (Fig. 2).

Sex hormones and portal hypertension

Forty-nine patients had available data on HVPG. Bioavailable \(T (r = 0.424, P = 0.003)\) and TT \((r = 0.303, P = 0.036)\) correlated significantly with absolute HVPG values. Clinically significant portal hypertension was present in 45 (91.8%) patients. Thirty-eight patients were found with HVPG \(\geq 12 \text{ mmHg} (77.6\%)\). Median BT (0.8 ng/mL [0.1–2] vs. 1.68 ng/mL [0.07–2.65]; \(P = 0.004\)) and TT (2.7 ng/mL [0.23–12.34] vs. 7 ng/mL [0.25–10]; \(P = 0.041\)) levels were significantly lower in patients with HVPG \(\geq 12 \text{ mmHg} \).
months of follow-up were not significantly different between the groups (decompensated/died 8.5 months [0.6–60 months] vs. others 9.1 months [0.1–77 months]; \( P = 0.344 \)). During follow-up, 5 patients developed variceal bleeding (14.3%), 3 SBP (8.6%), 11 refractory ascites (31.4%), 13 HE (37.1%), and 3 jaundice (8.6%). Significantly more patients in the group with low BT and TT met the composite end-point during follow-up (BT < 1.59 ng/mL 88.4% vs. BT > 1.59 ng/mL 11.6%, \( P = 0.009 \); TT < 6.25 ng/mL 76.1% vs. TT > 6.25 ng/mL 23.9%, \( P = 0.027 \)). Kaplan–Meier survival estimation found significant difference in median time to hepatic decompensation/death between patients with low BT (35.6 months [27–44] vs. 62.5 months [50–75], \( P = 0.002 \)) low TT (30.5 months [21–40] vs. 58 months [48–68], \( P < 0.001 \)), and elevated PRL (32.3 months [21–44] vs. 51.2 months [40–63], \( P = 0.018 \)) (Fig. 3).

For univariate analysis regarding the composite endpoint
see Table 3. Multivariate analysis was undertaken with four models including both CPS and MELD and/or BT and TT and found that a TT level < 6.25 ng/mL was associated with an increased risk for the composite end-point, even after adjusting for CPS and MELD and other relevant factors (model 1b: HR, 2.503; 95% CI, 1.214–5.157; \( P = 0.013 \); Model 2b: HR, 3.065; 95% CI, 1.523–6.169; \( P = 0.002 \)). In contrast, BT below the threshold of < 1.59 ng/mL did not attain statistical significance in any model (see Table 3).

**DISCUSSION**

**IN THIS STUDY,** we showed the significant potential of low total T levels as an independent marker for the prediction of hepatic decompensation and death in patients with cirrhosis. For the first time we described the association between portal hypertension and low T levels. We also found increasing PRL levels associated with liver dysfunction. The other sex hormones measured in our study (LH, FSH, and SHBG) showed only mild correlation with liver dysfunction (Tables 1, 2).

According to current concepts, the deficiency of T in cirrhosis is thought to be due to multiple factors including both primary and secondary hypogonadism.5,7 The inappropriately low LH levels over CPS in our data confirm this hypothesis (see Table 1 and Fig. 1). However, the underlying cause for the alterations of the HPG axis in cirrhosis is not yet fully understood. Studies that evaluated sex hormone status pre- and post-liver transplantation found that the HPG axis function improves after liver transplantation, suggesting that hepatic dysfunction plays an important role.5,9,10,25 Limited data exists on the prognostic value of estrogen in cirrhosis; in an Australian study,6 high circulating serum estrone levels were associated with higher MELD and adverse outcomes. In another study evaluating estrogen levels pre- and post-TIPS implantation, increased estrogen levels were found in patients after TIPS,11 which was explained by the impact of portosystemic shunting on hyperestrogenism in cirrhosis. Estrogens are generally
elevated in cirrhosis\textsuperscript{3,26,27} due to portosystemic shunting\textsuperscript{11,12} decreased hepatic metabolism, and increased peripheral aromatization of androgens into estrogens.\textsuperscript{1,5} Hyperestrogenism inhibits central gonadotropin (LH) production and stimulates SHBG production, which contributes to hypotestosteronism.\textsuperscript{2,5} Accordingly, further studies about the prognostic impact of estrogen levels in cirrhosis would be of interest. Approximately 45% of T is bound to SHBG, another 50% to albumin, and approximately 2% circulates as free T.\textsuperscript{5,7} Hyperestrogenism and low androgens contribute towards increased production of SHBG, which then leads to further reduction of biologically active free T due to increased binding.\textsuperscript{5,7} Prolactin is elevated in chronic liver disease, mostly due to dopaminergic system alterations and hyperestrogenism, and correlates well with parameters of liver dysfunction (also see Tables 1, 2) as previously described.\textsuperscript{4,8,10} Central inhibition of the GnRH secretion through PRL is thought to further contribute towards hypogonadism.\textsuperscript{5}

Low T has been previously described as an independent risk factor for mortality\textsuperscript{13,14,28} and major infection\textsuperscript{14} in cirrhosis. Low median T levels have been described in patients with severe HE, who were admitted to hospital, as well as patients with ascites.\textsuperscript{3,6} We found significant difference in median time to hepatic event in groups with low TT, low BT, and high PRL and significantly more patients in the group with low BT and TT met the composite endpoint during follow-up. Hence, we could for the first time show that low TT is an independent risk factor for hepatic decompensation and mortality during a long follow-up period. Bioavailable T did not attain statistical significance and this could be explained by the fact that TT measures all components of serum T: free T, albumin-bound T, and SHBG-bound T. Hence, in states of altered albumin and

Figure 3 Kaplan–Meier curves for bioavailable testosterone (T) (a), total T (b), and prolactin (PRL) (c) in men with cirrhosis, stratified according to optimal Youden index-determined cut-offs. Cum., cumulative. [Color figure can be viewed at wileyonlinelibrary.com]
SHBG production, total T levels are a more stable predictive marker. For the first time, an association between HVPB low BT and TT is described by our data. This can certainly be explained due to the reflection of cirrhosis severity through HVPB but also due to increased portosystemic shunting in patients with elevated HVPB, where ultimately estrogen increasingly bypasses the liver and centrally inhibits GnRH production, which then leads to secondary hypogonadism. Whether low T levels are a cause or just a significant biomarker for hepatic decompensation and mortality is not known yet. The most consequential hypothesis would be that T accurately reflects liver disease severity and therefore solely acts as a predictive biomarker. This hypothesis is partly accredited in a study in which intramuscular T injection vs. placebo in cirrhots with low T showed no significant difference in mortality. Another hypothesis suggests a link between T and systemic inflammation. Testosterone has been shown to suppress the innate and adaptive immune system, such as reduction of macrophage activation, lymphocyte numbers, and cytokine levels. However, the downregulation of GnRH in the hypothalamus in severe chronic disease due to increased inflammatory markers (interleukin-1 and -6 and tumor necrosis factor-α) perpetually leads to secondary hypogonadism. Similarly, inflammatory markers are commonly elevated in patients with cirrhosis, which is a consequence of endotoxemia due to pathological bacterial translocation from the gut. Low T was found as an independent risk factor for major infection therefore confirming the pathophysiologic rationale in a clinical

© 2018 The Authors.

Hepatology Research published by John Wiley & Sons Australia, Ltd on behalf of Japan Society of Hepatology.

Table 3 Univariate and multivariate Cox regression models to determine risk factors for mortality or decompensation during follow-up

| Variable                      | HR (95% CI) | P-value | HR (95% CI) | P-value | HR (95% CI) | P-value | HR (95% CI) | P-value |
|-------------------------------|-------------|---------|-------------|---------|-------------|---------|-------------|---------|
| Age                           | 1.025 (0.992–1.058) | 0.139 | NS          |         | NS          |         | NS          |         |
| CPS B: 2.349 (1.07–5.15)      | 0.033       |         | B: 2.08     | 0.092   | B: 2.31     | 0.048   | NS          |         |
| CPS C: 6.65 (2.577–17.19)     | <0.001      |         | C: 5.38     | 0.002   | C: 5.28     | 0.001   | NS          |         |
| HCC 2.079 (0.944–4.579)       | 0.069       |         | NS          |         | NS          |         | NS          |         |
| MELD 1.124 (1.045–1.209)      | 0.002       |         | NS          |         | NS          |         | NS          |         |
| Bioavailable T < 1.59 ng/mL   | 3.933       | 0.004   | 2.59        | 0.059   | 2.47        |         | NS          |         |
| Total T < 6.25 ng/mL          | 3.493       | <0.001  | <0.001      |         | NS          |         | 3.07 (1.52–6.17) | 0.002 |
| PRL >13.8 ng/mL               | 2.282       | 0.020   | NS          |         | NS          |         | NS          |         |
| Creatinine                    | 1.924       | 0.029   | NS          |         | NS          |         | NS          |         |
| Albumin 0.910 (0.863–0.961)   | 0.001       |         | 0.93 (0.88–0.99) | 0.036 | NS          |         | NS          |         |
| Presence of ascites 3.634     | <0.001      |         | 2.28 (1.12–4.64) | 0.023 | 3.15 (1.52–6.17) | 0.001 |
| Previous hepatic decompensation 1.815 | 0.052 |         | NS          |         | NS          |         | NS          |         |

MV model 1a: Significant variables in the multivariate Cox regression model (included variables: Child–Pugh score [CPS], hepatocellular carcinoma [HCC], bioavailable testosterone [T], creatinine, and previous hepatic decompensation).
MV model 1b: Significant variables in the multivariate Cox regression model (included variables: CPS, HCC, total T, creatinine, and previous hepatic decompensation).
MV model 2a: Significant variables in the multivariate COX regression model (included variables: Model for End-stage Liver Disease [MELD], HCC, bioavailable T, albumin, presence of ascites [yes/no], and previous hepatic decompensation).
MV model 2b: Significant variables in the multivariate Cox regression model (included variables: MELD, HCC, total T, albumin, presence of ascites [yes/no], and previous hepatic decompensation).

CI, confidence interval; HCC, hepatocellular carcinoma; HR, hazard ratio; MV, multivariate; NS, non significant (P > 0.1); PRL, prolactin.
study and suggesting low T as a marker not only of disease severity but also increased inflammation. Furthermore, an inverse relationship between C-reactive protein and T has been described. Sarcopenia has been described as an independent risk factor for mortality in cirrhosis. Testosterone has an important anabolic function in muscle mass homeostasis, hence, low T directly impairs prognosis by contributing towards evolution of sarcopenia. In our study, both BT and TT levels were significantly lower in sarcopenic patients. As sarcopenia is independently associated with adverse outcomes in patients with cirrhosis, the implementation of specific treatments for sarcopenia (e.g., T supplementation) might improve prognosis. In addition, it has been reported that low total T was an even better predictor for mortality than sarcopenia. Similar to our study, sarcopenia significantly correlated with MELD but not with CPS. In a recent randomized controlled trial, intramuscular T therapy increased bone and muscle mass, however, there was no difference in clinical events during follow-up. Accordingly, future studies should aim to assess whether T supplementation-induced amelioration of sarcopenia improves the outcome of patients with cirrhosis.

Several other treatment strategies for sarcopenia have been evaluated, and more recently, guidelines for diagnosis and nutritional support have been published. It is recommended that, in all patients with cirrhosis and malnutrition, optimal daily protein intake should not be lower than 1.2–1.5 g/kg per day and overall energy intake should not fall below 35 kcal/kg. Late evening oral nutritional supplementation is key; moreover, supplementation with branched-chain amino acids has shown positive results. Other treatment options include physical exercise or ammonia-lowering strategies, although further studies in these fields are needed before they can be recommended for daily clinical practice. Interestingly, low T levels have been associated with increased risk for all-cause mortality within several other chronic diseases.

Limitations of our study certainly are the relatively small number of patients included, although the prospective setting and tight follow-up in the outpatient clinic as well as the long-term follow-up period puts this into perspective. Also excluding patients with HE comprises a possible selection bias. Nevertheless, previous studies have described significantly low T levels in patients with HE; hence we would expect similar results if patients with HE had been included. Additionally, data on estrogen levels are missing, and association with HVPG in our study would have been interesting. Strengths of our study are the long-term follow-up and detailed record of hepatic decompensation, liver transplantation, and mortality. Furthermore, we could for the first time show the association between HVPG and low T levels, indicating a negative effect of increased portosystemic shunting on (secondary) hypogonadism.

In conclusion, sex hormone status in cirrhotic men is frequently deranged. Total T is an independent risk factor for hepatic decompensation and mortality. Patients below the threshold of 6.25 ng/mL for TT are at increased risk and should be monitored closely. Taking into account recent results that T therapy in cirrhotic men is safe, further studies are warranted to determine whether reversing hypotestosteronism and sarcopenia has a beneficial effect on long-term clinical outcomes.

REFERENCES

1. Zietz B, Lock G, Plach B et al. Dysfunction of the hypothalamic-pituitary-glandular axes and relation to Child–Pugh classification in male patients with alcoholic and virus-related cirrhosis. *Eur J Gastroenterol Hepatol* 2003; 15: 495–501.

2. Mowat NA, Edwards CR, Fisher R, McNeilly AS, Green JR, Dawson AM. Hypothalamic-pituitary-gonadal function in men with cirrhosis of the liver. *Gut* 1976; 17: 345–50.

3. De Besi L, Zucchetta P, Zotti S, Mastrogiacomo I. Sex hormones and sex hormone binding globulin in males with compensated and decompensated cirrhosis of the liver. *Acta Endocrinol* 1989; 120: 271–6.

4. Mooradian AD, Shamma A, McNeilly SA, Green JR, McCaughan GW. Hypothalamic-pituitary-gonadal dysfunction in men with non-alcoholic liver cirrhosis. *Andrologia* 1985; 17: 72–9.

5. Foresta C, Schipilliti M, Carleglia FA, Lenzi A, D’Amico D. Male hypogonadism in cirrhosis and after liver transplantation. *J Endocrinol Invest* 2008; 31: 470–8.

6. Sinclair M, Gow PJ, Angus PW et al. High circulating oestrone and low testosterone correlate with adverse clinical outcomes in men with advanced liver disease. *Liver Int* 2016; 36: 1619–27.

7. Sinclair M, Grossmann M, Gow PJ, Angus PW. Testosterone in men with advanced liver disease: abnormalities and implications. *J Gastroenterol Hepatol* 2015; 30: 244–51.

8. Wang YL, Wu JC, Lee SD, Tsai YT, Lo KJ. Gonadal dysfunction and changes in sex hormones in postnecrotic cirrhotic men: a matched study with alcoholic cirrhotic men. *Hepatogastroenterology* 1991; 38: 531–4.

9. Handelsman DJ, Strasser S, McDonald JA, Conway AI, McCaughan GW. Hypothalamic-pituitary-testicular function in end-stage non-alcoholic liver disease before and after liver transplantation. *Clin Endocrinol (Oxf)* 1995; 43: 331–7.

10. Madersbacher S, Ludvik G, Stulnig T, Gunrberger T, Maior U. The impact of liver transplantation on endocrine status in men. *Clin Endocrinol (Oxf)* 1996; 44: 461–6.

11. Nolte W, Schindler CG, Figulla HR et al. Increase of serum estradiol in cirrhotic men treated by transjugular intrahepatic portosystemic stent shunt. *J Hepatol* 2001; 34: 818–24.
12 Van Thiel DH, Gavaler JS, Cobb CF, McClain CJ. An evaluation of the respective roles of portosystemic shunting and portal hypertension in rats upon the production of gonadal dysfunction in cirrhosis. *Gastroenterology* 1983; 85: 154–9.

13 Grossmann M, Hoermann R, Gani L et al. Low testosterone levels as an independent predictor of mortality in men with chronic liver disease. *Clin Endocrinol (Oxf)* 2012; 77: 323–8.

14 Sinclair M, Cow PJ, Grossmann M, Shannon A, Hoermann R, Angus PW. Low serum testosterone is associated with adverse outcome in men with cirrhosis independent of the Model for End-stage Liver Disease score. *Liver Transpl* 2016; 22: 1482–90.

15 Kim S, Kwon H, Park JH et al. A low level of serum total testosterone is independently associated with nonalcoholic fatty liver disease. *BMC Gastroenterol* 2012; 12: 69.

16 Peck-Radosavljevic M, Trauner M, Schreiber F. Austrian consensus on the definition and treatment of portal hypertension and its complications. *Endoscopy* 2005; 37: 667–73.

17 Peck-Radosavljevic M, Angermayr B, Datz C et al. Austrian consensus on the definition and treatment of portal hypertension and its complications (Billroth II). *Wien Klin Wochenschr* 2013; 125(7–8): 200–19.

18 European Association for the Study of the Liver. EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis. *J Hepatol* 2010; 53: 397–417.

19 Plauth M, Cabre E, Riggio O et al. ESPEN guidelines on enteral nutrition: liver disease. *Clin Nutr* 2006; 25: 285–94.

20 Plauth M, Merli M, Kondrup J et al. ESPEN guidelines for nutrition in liver disease and transplantation. *Clin Nutr* 1997; 16: 43–55.

21 Vermeulen A, Verdonck L, Kaufman JM. A critical evaluation of simple methods for the estimation of free testosterone in serum. *J Clin Endocrinol Metab* 1999; 84: 3666–72.

22 Ferlitsch M, Reiberger T, Hoke M et al. von Willebrand factor as new noninvasive predictor of portal hypertension, decompensation and mortality in patients with liver cirrhosis. *Hepatology* 2012; 56: 1439–47.

23 Ferlitsch A, Bota S, Paternostro R et al. Evaluation of a new balloon occlusion catheter specifically designed for measurement of hepatic venous pressure gradient. *Liver Int* 2015; 35: 2115–20.

24 Nishikawa H, Shiraki M, Hiramatsu A et al. Japan Society of Hepatology guidelines for sarcopenia in liver disease (1st edition): recommendation from the working group for creation of sarcopenia assessment criteria. *Hepatol Res* 2016; 46: 951–63.

25 Seehofer D, Steinmueller T, Graef KJ et al. Pituitary function test and endocrine status in patient with cirrhosis of the liver before and after hepatic transplantation. *Ann Transplant* 2002; 7: 32–7.

26 Sinclair M, Cow PJ, Angus PW et al. High circulating estrone and low testosterone correlate with adverse clinical outcomes in men with advanced liver disease. *Liver Int* 2016; 36: 1619–27.

27 Pignata S, Daniele B, Galati MG et al. Oestradiol and testosterone blood levels in patients with viral cirrhosis and hepatocellular carcinoma. *Eur J Gastroenterol Hepatol* 1997; 9: 283–6.

28 Sinclair M, Grossmann M, Angus PW et al. Low testosterone as a better predictor of mortality than sarcopenia in men with advanced liver disease. *J Gastroenterol Hepatol* 2016; 31: 661–7.

29 Sinclair M, Grossmann M, Hoermann R, Angus PW, Cow PJ. Testosterone therapy increases muscle mass in men with cirrhosis and low testosterone: a randomised controlled trial. *J Hepatol* 2016; 65: 906–13.

30 Maggio M, Basaria S, Ble A et al. Correlation between testosterone and the inflammatory marker soluble interleukin-6 receptor in older men. *J Clin Endocrinol Metab* 2006; 91: 345–7.

31 Muehlenbein MP, Bibbiescas RG. Testosterone-mediated immune functions and male life histories. *Am J Hum Biol* 2005; 17: 527–58.

32 Gold SM, Chalifoux S, Giisser BS, Voskuhl RR. Immune modulation and increased neurotrophic factor production in multiple sclerosis patients treated with testosterone. *J Neuroinflammation* 2008; 5: 32.

33 Reiberger T, Ferlitsch A, Payer BA et al. Non-selective betablocker therapy decreases intestinal permeability and serum levels of LBP and IL-6 in patients with cirrhosis. *J Hepatol* 2013; 58(5): 911–21.

34 Kupelian V, Chiu GR, Araujo AB, Williams RE, Clark RV, McKinlay JB. Association of sex hormones and C-reactive protein levels in men. *Clin Endocrinol (Oxf)* 2010; 72(4): 527–33.

35 Montano-Loza AJ, Meza-Junco J, Prado CM et al. Muscle wasting is associated with mortality in patients with cirrhosis. *Clin Gastroenterol Hepatol* 2012; 10: 166–73.

36 Kim HY, Jang JW. Sarcopenia in the prognosis of cirrhosis: going beyond the MELD score. *World J Gastroenterol* 2015; 21: 7637–47.

37 European Association for the Study of the Liver. EASL Clinical Practice Guidelines on nutrition in chronic liver disease. *J Hepatol* 2018. https://doi.org/10.1016/j.jhep.2018.06.024.

38 Nakaya Y, Harada N, Kakui S et al. Severe catabolic state after prolonged fasting in cirrhotic patients: effect of oral branched-chain amino-acid-enriched nutrient mixture. *J Gastroenterol* 2002; 37: 531–6.

39 Yoshida T, Muto Y, Moriwaki H, Yamato M. Effect of long-term oral supplementation with branched-chain amino acid granules on the prognosis of liver cirrhosis. *Gastroenterol Jpn* 1989; 24: 692–8.

40 Hyde Z, Norman PE, Flicker L et al. Low free testosterone predicts mortality from cardiovascular disease but not other causes: the Health in Men Study. *J Clin Endocrinol Metab* 2012; 97: 179–89.

41 Araujo AB, Dixon JN, Suarez EA, Murad MH, Guey LT, Wittet GA. Clinical review: endogenous testosterone and mortality in men: a systematic review and meta-analysis. *J Clin Endocrinol Metab* 2011; 96: 3007–19.